GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice

Objective In addition to improve glucose intolerance, recent studies suggest that glucagon-like peptide-1 (GLP-1) receptor agonism also decreases triglyceride (TG) levels. The aim of this study was to evaluate the effect of GLP-1 receptor agonism on very-low-density lipoprotein (VLDL)-TG production and liver TG metabolism. Experimental Approach The GLP-1 peptide analogues CNTO3649 and exendin-4 were continuously administered subcutaneously to high fat diet-fed APOE*3-Leiden transgenic mice. After 4 weeks, hepatic VLDL production, lipid content, and expression profiles of selected genes involved in lipid metabolism were determined. Results CNTO3649 and exendin-4 reduced fasting plasma glucose (up to −30% and −28% respectively) and insulin (−43% and −65% respectively). In addition, these agents reduced VLDL-TG production (−36% and −54% respectively) and VLDL-apoB production (−36% and −43% respectively), indicating reduced production of VLDL particles rather than reduced lipidation of apoB. Moreover, they markedly decreased hepatic content of TG (−39% and −55% respectively), cholesterol (−30% and −55% respectively), and phospholipids (−23% and −36% respectively), accompanied by down-regulation of expression of genes involved in hepatic lipogenesis (Srebp-1c, Fasn, Dgat1) and apoB synthesis (Apob). Conclusion GLP-1 receptor agonism reduces VLDL production and hepatic steatosis in addition to an improvement of glycemic control. These data suggest that GLP-receptor agonists could reduce hepatic steatosis and ameliorate dyslipidemia in patients with type 2 diabetes mellitus.

[1]  S. Mohanty,et al.  Nonalcoholic Fatty Liver Disease: A Review and Update , 2010, Digestive Diseases and Sciences.

[2]  A. Garber.  Long-Acting Glucagon-Like Peptide 1 Receptor Agonists , 2011, Diabetes Care.

[3]  R. Hegele,et al.  Naringenin Prevents Dyslipidemia, Apolipoprotein B Overproduction, and Hyperinsulinemia in LDL Receptor–Null Mice With Diet-Induced Insulin Resistance , 2009, Diabetes.

[4]  S. Grundy,et al.  Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. , 1996, Journal of lipid research.

[5]  M. Foretz,et al.  Sterol-regulatory-element-binding protein 1c mediates insulin action on hepatic gene expression. , 2001, Biochemical Society transactions.

[6]  E. Tomás,et al.  GLP-1 (9–36) Amide Metabolite Suppression of Glucose Production in Isolated Mouse Hepatocytes , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[7]  M. Beylot,et al.  Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. , 2003, Diabetes & metabolism.

[8]  Michael Stumvoll,et al.  Type 2 diabetes: principles of pathogenesis and therapy , 2005, The Lancet.

[9]  P. J. Larsen,et al.  Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites , 1995, The European journal of neuroscience.

[10]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[11]  Betteridge.  Diabetic dyslipidaemia , 1999, Diabetes, obesity & metabolism.

[12]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[13]  W. Pan,et al.  Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier , 2002, Journal of Molecular Neuroscience.

[14]  H. Pijl,et al.  GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. , 2010, American journal of physiology. Endocrinology and metabolism.

[15]  M. Taskinen,et al.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes , 2006, Diabetologia.

[16]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[17]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[18]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[19]  S. Kahn,et al.  Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.

[20]  Henry N. Ginsberg,et al.  Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. , 1992, The Journal of clinical investigation.

[21]  C. Bailey,et al.  Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic β-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[22]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[23]  H. Pijl,et al.  CNTO736, a Novel Glucagon-Like Peptide-1 Receptor Agonist, Ameliorates Insulin Resistance and Inhibits Very Low-Density Lipoprotein Production in High-Fat-Fed Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.

[24]  S. Woods,et al.  Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity , 2009, The Journal of Neuroscience.

[25]  E. Parks,et al.  Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. , 2006, The Journal of clinical endocrinology and metabolism.

[26]  A. Young,et al.  Dose–response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats , 2005, Diabetologia.

[27]  M. Vivarelli,et al.  Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[28]  R. Muthupillai,et al.  Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes , 2011, Obesity.

[29]  D. Drucker,et al.  Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis , 2008, Diabetes.

[30]  R. Frants,et al.  Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. , 1994, The Journal of clinical investigation.

[31]  D. Klonoff,et al.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.

[32]  D. Drucker,et al.  The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice , 2010, Diabetologia.

[33]  J. Holst,et al.  Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.

[34]  P. J. Larsen,et al.  Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem , 1997, Neuroscience.

[35]  C. E. West,et al.  Separation of plasma lipoproteins by density-gradient ultracentrifugation. , 1975, Analytical biochemistry.

[36]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[37]  Christoph Handschin,et al.  Hyperlipidemic Effects of Dietary Saturated Fats Mediated through PGC-1β Coactivation of SREBP , 2005, Cell.

[38]  E. Liao.  Management of type 2 diabetes: new and future developments in treatment. , 2012, The American journal of medicine.

[39]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[40]  F. Anania,et al.  Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway , 2010, Hepatology.

[41]  R. Frants,et al.  Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. , 1993, The Journal of biological chemistry.

[42]  P. Dandona,et al.  Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[43]  M. Hellerstein,et al.  Model for measuring absolute rates of hepatic de novo lipogenesis and reesterification of free fatty acids. , 1993, The American journal of physiology.

[44]  F. Anania,et al.  Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice , 2006, Hepatology.